• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.

作者信息

Ushakumari Deepu S, Sladen Robert N

机构信息

Columbia University Irving Medical Center, New York, New York (R.N.S.).

出版信息

Anesthesiology. 2024 Feb 1;140(2):346-348. doi: 10.1097/ALN.0000000000004776.

DOI:10.1097/ALN.0000000000004776
PMID:37982170
Abstract
摘要

相似文献

1
ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.美国麻醉医师协会基于共识的胰高血糖素样肽-1受体激动剂治疗患者术前管理指南。
Anesthesiology. 2024 Feb 1;140(2):346-348. doi: 10.1097/ALN.0000000000004776.
2
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity.GLP-1 受体激动剂在肥胖治疗中的提供不平等。
Nat Med. 2024 Jan;30(1):22-25. doi: 10.1038/s41591-023-02669-x.
3
Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure.测量血压：胰高血糖素样肽-1受体激动剂对血压影响的最佳评估
Diabetes Obes Metab. 2024 Aug;26(8):3003-3005. doi: 10.1111/dom.15631. Epub 2024 May 5.
4
First Large Study of GLP-1 Receptor Agonists During Pregnancy.首次关于孕期使用胰高血糖素样肽-1受体激动剂的大型研究。
JAMA. 2024 Jan 23;331(4):280. doi: 10.1001/jama.2023.26112.
5
Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.患者总结：胰高血糖素样肽-1受体激动剂与美国老年2型糖尿病患者自杀意念和行为风险
Ann Intern Med. 2024 Aug;177(8):I14. doi: 10.7326/P24-0004. Epub 2024 Jul 16.
6
A commentary on 'Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials'.关于“胰高血糖素样肽-1受体激动剂与癌症风险的关联——来自药物靶点孟德尔随机化和临床试验的证据”的评论
Int J Surg. 2024 Sep 1;110(9):6034-6035. doi: 10.1097/JS9.0000000000001725.
7
[Not Available].[无可用内容]
MMW Fortschr Med. 2024 Jun;166(10):11. doi: 10.1007/s15006-024-4002-4.
8
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
9
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.胰高血糖素样肽-1受体激动剂与2型糖尿病患者严重肝脏事件的关联：一项斯堪的纳维亚队列研究。
Hepatology. 2024 Jun 1;79(6):1255-1257. doi: 10.1097/HEP.0000000000000768. Epub 2024 Feb 9.
10
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.胰高血糖素样肽-1及其受体激动剂：它们在2型糖尿病管理中的作用。
Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15.

引用本文的文献

1
Preoperative Use of Liraglutide in Weight Loss Surgery: Limitations and Future Research.利拉鲁肽在减肥手术中的术前应用：局限性与未来研究
Obes Surg. 2025 Sep 11. doi: 10.1007/s11695-025-08257-x.
2
2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists.2025年关于胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽受体激动剂围手术期使用的澳大利亚糖尿病学会/澳大利亚和新西兰麻醉医师学会/胃肠病学会澳大利亚分会/澳大利亚肥胖症协会临床实践建议
Anaesth Intensive Care. 2025 Aug 14:310057X251355288. doi: 10.1177/0310057X251355288.
3
Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.
胰高血糖素样肽-1受体激动剂对上消化道内镜检查的影响：一项更新的系统评价和荟萃分析。
Surg Endosc. 2025 Jul 9. doi: 10.1007/s00464-025-11962-4.
4
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning.探索胰高血糖素样肽-1受体激动剂的副作用：以确保其最佳定位。
Diabetes Metab J. 2025 Jul;49(4):525-541. doi: 10.4093/dmj.2025.0242. Epub 2025 Jul 1.
5
GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.美学手术中的胰高血糖素样肽-1激动剂：对围手术期结果和身体塑形手术的影响
Aesthetic Plast Surg. 2025 Jul 2. doi: 10.1007/s00266-025-05015-3.
6
Ten Top Tips for the Management of GLP-1 Receptor Agonists in Adults within Primary Care.基层医疗中成人GLP-1受体激动剂管理的十大顶级建议。
Obes Facts. 2025 May 19:1-6. doi: 10.1159/000546472.
7
Outcomes of retained gastrointestinal debris during upper endoscopy.上消化道内镜检查期间胃肠道异物残留的结局
Endosc Int Open. 2025 Apr 4;13:a25442468. doi: 10.1055/a-2544-2468. eCollection 2025.
8
Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity.基于胰高血糖素样肽-1的疗法在2型糖尿病和肥胖症管理中的分子药理学
Integr Pharm Res Pract. 2025 Apr 6;14:59-72. doi: 10.2147/IPRP.S503501. eCollection 2025.
9
Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.比较不同肥胖治疗方式后发生胃轻瘫的风险：司美格鲁肽与安非他酮-纳曲酮与袖状胃切除术——一项回顾性队列研究。
BMJ Open Gastroenterol. 2025 Apr 2;12(1):e001704. doi: 10.1136/bmjgast-2024-001704.
10
Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.胰高血糖素样肽-1受体激动剂治疗患者胃肠道内镜检查安全性的证据报告：系统评价与荟萃分析
Diagnostics (Basel). 2025 Mar 19;15(6):770. doi: 10.3390/diagnostics15060770.